Lonza Group stock holds ground as investors weigh recent contract wins and margin trends

Lonza Group stock reflects a balance between new contract momentum and the margin reset after the 2023 Novartis contract exit, with investors watching execution on the companys CHF 6.2 billion long term manufacturing backlog and 2024 profitability targets.

Lonza Group (ISIN CH0013841017) stock continues to reflect a balance between long term growth from biologics manufacturing and the profitability reset that followed the exit from a major contract in 2023, as investors focus on the companys sizeable order backlog and margin trajectory in 2024 and beyond.

Revenue base and margin reset after 2023

According to the companys published 2023 figures, Lonza reported total sales of around CHF 6.7 billion for the 2023 financial year, providing a broad revenue base after several years of expansion in biologics and small molecules manufacturing.

Within that figure, Lonza disclosed that the impact from the termination of a large contract for the manufacture of an originator biological drug translated into a meaningful adjustment to the growth profile of its biologics operations, and management highlighted a renewed focus on portfolio mix and operational efficiency to support margins after 2023.

For investors, the combination of a multi billion franc revenue base and a business mix increasingly skewed to biologics and cell and gene technologies means that small changes in utilization and pricing can have a visible effect on profitability.

Backlog of CHF 6.2 billion underpins medium term visibility

Lonza has communicated that its long term manufacturing backlog stands at approximately CHF 6.2 billion, providing several years of revenue visibility across its key biologics and small molecules platforms.

This backlog reflects a mix of commercial and late stage clinical programs, and management has emphasized that the composition of the order book has become more diversified after the loss of the large Novartis contract for the production of the multiple sclerosis drug Kesimpta, reducing dependence on any single customer relationship.

Compared with earlier periods when a higher proportion of volumes were tied to a few large originator contracts, the CHF 6.2 billion backlog is designed to smooth revenue and support a more balanced margin profile, even if individual projects ramp or roll off at different times.

Biologics and small molecules drive scale

Lonzas business is structured around biologics, small molecules, cell and gene, and capsule and health ingredients, with biologics and small molecules together accounting for the majority of group sales in recent reporting periods.

The company has pointed out that demand for outsourced biologics development and manufacturing has remained resilient, supported by a growing pipeline of monoclonal antibodies, complex biologics, and new modalities where originator pharma and biotech groups often prefer to partner with specialized contract manufacturers rather than build capacity in house.

In small molecules, Lonza serves both originator and generic customers, and the business benefits from a combination of long term commercial supply agreements and shorter duration development work, which together contribute to asset utilization and cash generation.

Profitability focus after contract loss

The termination of the Kesimpta contract with Novartis was a key turning point for Lonza, as it removed a large volume contributor from the biologics pipeline and required management to adjust capacity planning, cost allocation, and capital expenditure priorities.

Following that change, the company has guided investors toward a medium term margin framework that reflects a shift from very high utilization levels on a few large assets to a more diversified mix in which operational efficiency, cost management, and disciplined capital allocation are central to sustaining attractive returns.

For investors, this means that while the long term demand trend for biologics and advanced therapies remains positive, the near term trajectory of Lonzas margins depends heavily on the pace at which new contracts ramp to fill capacity that was previously occupied by the Novartis program and on the terms of these newer agreements.

Representative product and service offering

One representative example of Lonzas capabilities is its end to end biologics offering, which spans cell line development, process development, clinical scale manufacturing, and large scale commercial production for monoclonal antibodies and other complex biologics.

This integrated offering allows customers to move from early development through to market supply within a single partner framework, reducing technology transfer risk and supporting faster scale up, and has been an important driver of the companys ability to secure large, multi year contracts across different therapeutic areas.

Lonza Group stock and market positioning

Lonza Group stock is listed on SIX Swiss Exchange and forms part of the Swiss large cap universe, where it is often grouped with other European life science suppliers and contract development and manufacturing organizations in sector comparisons.

For shareholders, the key variables now are the pace at which the CHF 6.2 billion long term manufacturing backlog converts into revenue, the degree to which the post 2023 margin framework can be defended or improved as newer contracts mature, and the extent to which biologics, small molecules, and cell and gene technologies continue to attract investment from originator pharma and biotech customers.

Lonza Group at a glance

• Company: Lonza Group Ltd
• ISIN: CH0013841017
• Ticker: SIX: LONN
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Health Care / Life Sciences Tools and Services
• Index membership: Swiss large cap universe